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ABSTRACT  
Aims: This study investigated the antioxidant activity and the 90 days subchronic toxicity of the standardized LAMIC phytomedicine prototype 
based on aqueous extracts from Lannea microcarpa trunk bark. 
Methods: Three spectrophotometric methods were used to evaluated the antioxidant activity of LAMIC which were 2,2-Diphenyl-1-
picrylhydrazyl (DPPH) free radical, 2,2’-azinobis(3-ethylbenzolin-6-sulphonate) (ABTS) radical scavenging assays and ferric reducing 
antioxidant power (FRAP) assays. For the standardized LAMIC subchronic toxicity study, male and female Wistar rats were used by daily oral 
administration at doses of 500, 1000 and 1500 mg/kg bw consecutively for 90 days.  
Results: The LAMIC extract exhibit better inhibitory activity against DPPH radical than ABTS radical with respective IC50 values of 45.38±3.21 
µg/mL and 66.45±18.76 µg/mL, while FRAP assay exhibit antioxidant activity of 211.34±15.92 mmol EAA/g.  
Subchronic oral administration of LAMIC was well-tolerated at all tested doses. No behavioral and physiological changes and mortality were 
observed. The LAMIC extract did not present any impact on general hematological parameters and biochemical parameters. Moreover, no 
significant changes were raised in organ and body weight of treated groups compared to the Control group.  
Conclusion: These results support that LAMIC prototype was a valuable source of natural antioxidants and no toxicity was associated to it s 
long terms oral consumption in rats indicating a potential application as a cardiovascular protective formulation.  
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INTRODUCTION 
According to World Health Organization, more than 80% of 
rural populations living in developing countries depend on 
traditional medicine for the management of priority 
pathologies. Indeed, the majority of these populations is 
poor and the management of diseases is expensive in 
modern medicine hence a renewed interest in medicine and 
traditional pharmacopoeia. This is the case of high blood 
pressure still called "silent killer" who is treated for life and 
whose conventional drugs are very expensive. This 
pathology is constantly increasing among African 
populations like other developed countries. The estimate of 
the total number of adults with hypertension in 2000 was 
972 million, of which 333 million in economically strong 
countries compared to 639 million in developing countries. 
By 2025, these numbers will rise to 60% for 1.56 billion 
hypertensive patients 1. Thus, the medium and long-term 
management of this pathology rightly calls for an 
intensification of the research / development of new drugs, 
more accessible, cheaper with very few side effects and 
based on the plants or recipes used traditionally. It is in this 
context that much research has been undertake to develop 
phytomedicine for the management of priority pathologies 
including arterial hypertension, diabetes, inflammatory 
diseases, etc. In Burkina Faso, the Institute for Research in 
Health Sciences has developed a standardized 
phytomedicine prototype called LAMIC, formulated from a 
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plant extract called Lannea microcarpa Engl. and K. Krause 2. 
In traditional medicine, this species is widely used in 
Burkina Faso to treat various pathologies including 
hypertension.  
Previous studies have shown that extracts of Lannea 
microcarpa showed no in vitro cytotoxic effect on cell 
viability. In vivo, no anti-inflammatory (cottonseed oil) or 
pro-inflammatory effects were detected 3. In addition, 
antioxidant activities have already been demonstrated in 
fruit extracts of the plant 4. In vitro, the vasodilation effect of 
the aqueous extract of the trunk bark of Lannea microcarpa 
on the vascular smooth muscle has also been investigated 5. 
Another study has shown that extracts from Lannea 
microcarpa have diuretic properties and are cyclic 
nucleotides phosphodiesterase inhibitors. Above all, studies 
have classified the aqueous extract of this plant as 
moderately toxic, while an investigation of the oral subacute 
toxicity of Lannea microcarpa extract for 28-day showed no 
toxicity in animals 6. Others authors have also show no 
toxicity effect revealed in acute and subacute oral toxicity 
study using an aqueous extract of Lannea microcarpa stem 
bark 7. Chemically, bark of trunk from Lannea microcarpa 
has highlighted the presence of sterols, triterpenes, 
anthracenosides, steroidal and triterpenic glycosides, 
coumarin derivatives, saponosides, reducing compounds, 
anthocyanin and phenolic compounds (tannins) 3, 5, 8. 
However, no study to date has been undertaken to verify 
that the LAMIC phytomedicine prototype after formulation 
has retained its potential biological effects and would also be 
safe for its possible use in humans. 
It is in this perspective that the present work was 
undertaken to explore the antioxidant activity and 
subchronic toxicity of this formulation in order to provide 
scientific evidence in favor of the therapeutic properties and 
safety of use of this phytomedicine prototype LAMIC. 
MATERIAL AND METHODS 
Reagents  
Trolox; 2,2-diphenyl-1-picrylhydrazyl (DPPH); 2,2’-
azinobis(3-ethylbenzolin-6-sulphonate) (ABTS); Analytical 
solvents (Ethyl acetate; methanol; chloroform; formic acid; 
n-hexane; chloroform; Acetone) were from sigma Aldrich 
(Steinheim, Germanany); Iron chloride (FeCl3) were from 
Fluka Chemie. 
Plant material 
The process of Lannea microcarpa Engl. and K. Krause 
(Anacardiaceae) trunk barks at the basis of LAMIC were 
already describes 9. Briefly, the trunk bark of the plant was 
harvested in January 2015 on the site of Gampèla, a locality 
located 18 km east of Ouagadougou. A sample had been 
identify by a botanist from the Ecology Laboratory of the 
University of Ouagadougou and a voucher specimen had 
been deposited (Voucher number: HNBU 361). The collected 
samples were air-dried in room without solar light and dust, 
and were powdered with a mechanical grinder and stocked 
until used.  
Phytomedicine prototype LAMIC 
LAMIC is a phytomedicine prototype formulated at the IRSS 
and was based on freeze-dried aqueous extract of the trunk 
bark of Lannea microcarpa Engl and K. Krause 2.  
After the formulation, the macroscopic and organoleptic 
characteristics, the pH, the total ash content, the residual 
moisture content (THR), the microbial quality were 
determined before the availability of the LAMIC 
phytomedicine prototype used in the studies on the 
antioxidant and toxicological activity 2. The antioxidant 
effect and toxicological investigations were done on the 
LAMIC prototype.  
Experimental animals 
Adult rats (males and females) of Wistar strain aged three to 
four months (3-4) months weighing on average 173.48±5.34 
g were used. They were provided by the pet shop of the 
Health Sciences Research Institute (IRSS), where they were 
fed wheat cake (29% protein) and running water. They were 
raised under air conditioning (23-25 °C) in the presence of 
light (12/24 h) and between 60% to 75% humidity. They 
were used to evaluate the subchronic toxicity of the LAMIC 
prototype. Male normotensive Wistar rats, 191.70±24.25 g, 
from the Research Institute for Health Sciences (Burkina 
Faso) pet stores were use. Animal experimental procedures 
were in accordance in accordance with the Declaration of 
Helsinki for animal experiments 10.  
Antioxidant activity 
The in vitro antioxidant potential of LAMIC phytomedicine 
prototype were investigated using DPPH, FRAP and ABTS 
antioxidant methods.  
2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical 
scavenging assay 
The antioxidant activity of LAMIC was evaluated by the 2,2-
Diphenyl-1-picrylhydrazyl (DPPH) method previously 
describe by Kim et al. 11. This method is based on the 
reduction of the absorbance of the stable free DPPH° at 490 
nm, in the presence of an H° radical donor. For that, DPPH (1 
mg/25 mL in absolute methanol) and Trolox (positive 
control) were used. Then, a series of eight successive 
dilutions at ½ was carried out from a stock solution (5 
mg/mL in ethanol 70%) of aqueous extract of LAMIC. The 
test sample (20 µL) was mixed with 200 µL of DPPH and 
then incubate for 30 min at room temperature. After the 
incubation period, the absorbance was measured at 490 nm 
against a blank, using a spectrophotometer (UV-VIS, Biorad 
model 680). A DPPH inhibition curve (in percent) was 
plotted against the concentration of the sample and the 
DPPH radical scavenging 50% (IC50) was calculated by the 
following formula: IC50 (%) = (AbsBlank-AbsExtract)/AbsBlank x 
100 
With AbsBlank = Absorbance of the Blank; AbsExtract = 
Absorbance of the LAMIC aqueous extract. Then, the Anti 
Radical Power (ARP) was determined by the formula: ARP = 
1/IC50.  
Ferric reducing antioxidant power (FRAP) assay 
The Ferric reducing antioxidant power (FRAP) assay was 
conducted according to Hinneburg et al. 12, in which the 
ability of the LAMIC aqueous extract to reduce Fe3+ to Fe2+ 
was determined. LAMIC sample solution (0.5 mL of 0.1 
mg/mL in methanol) was mixed with phosphate buffer (1.25 
mL of 0.2 M, pH 6.6) and potassium hexacyanoferrate (1.25 
mL of 1% in water). After 30 min of incubation (50°C), 1.25 
mL of trichloroacetic acid (10% in water) was added and the 
mixture was centrifuged at 2000 rpm for 10 min. The 
supernatant (0.625 mL) was mixed with distilled water 
(0.625 mL) and 0.125 mL of freshly prepared FeCl3 (1% in 
water) and then absorbance was read at 700 nm with a 
spectrophotometer (Agilent 8453) equipped with UV-vis 
ChemStation software. Ascorbic acid was used as standard 
to plot a calibration curve (R2= 0.99). Three independent 
experiments were performed in triplicate. Reducing power 
was expressed as mmol Ascorbic Acid Equivalent per gram 
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(mmol EAA/g) of dry extract according to the following 
formula: C = (c × D)/(M × Ci) 
With  C = concentration of reducing compounds in mmol 
EAA/g of solids 
c = concentration of the sample read 
D = dilution factor of the stock extract solution 
Ci = concentration of the mother extract solution 
M = molar mass of Ascorbic acid (176.1 g/mol) 
ABTS radical scavenging assay 
The free radical inhibition capacity of LAMIC aqueous 
extract was evaluated according to the method previously 
described by Re et al. using ABTS 13. 
The ABTS stock solution was prepared in distilled water 
(19.2 mg/5 mL, m/v), in which 3.312 mg of potassium 
persulfate was added at 12h-16h prior to the experiment 
and the mixture maintained at ambient temperature 
(protected from light). After that, 4.5 mL of the mixture was 
diluted in 220 mL of analytical ethanol.  
For the test, 20 µL of the LAMIC aqueous extract sample (5 
mg/mL) in 200 µL ABTS solution was used and Trolox was 
used as positive control. The whole was protected from light 
at room temperature (25°C) for 30 minutes and the 
absorbance were read at 734 nm using a spectrophotometer 
(UV-VIS, Biorad model 680). The Trolox Equivalent 
Antioxidant Capacity (TEAC) was calculated according to the 
following formula: TEAC = ARPExtract/ARPTrolox. Three 
independent experiments were performed in triplicate. 
90-days subchronic toxicity in rats 
Subchronic toxicity has been evaluated according to the 
guidelines 408 of the Organization for Economic 
Development and Cooperation 14. Wistar rats were randomly 
divided into four (04) groups (10 males and 10 females per 
group): 
 The Control group (Group 1) received vehicle daily oral 
gavage throughout the course of the study.  
 The experiment groups (Group 2-4) were orally 
administrated LAMIC aqueous extract at doses of 500, 
1000 and 1500 mg/kg body weight respectively, for 90 
days.  
Body weight and food consumption were recorded weekly 
while, water intake were daily recorded. At the end of the 
study, rats were anesthetized with ketamine and blood 
sample were obtained by cardiac puncture for serum 
biochemical studies. After blood collection, organs (kidneys, 
heart, lungs, liver, spleen, testes) were excised, weighed 
using an analytical balance and macroscopically exanimated. 
All organs were stored for further analysis. Blood samples 
(in the tubes without anticoagulant) were then centrifuged 
at 3000 rpm for 10 min. The collected sera, stored at -20°C, 
were used for biochemical assay to determine relative 
parameters of alanine aminotransferase (ALAT), aspartate 
aminotransferase (AST), calcium, chloride, phosphorus, 
glucose, total protein, total cholesterol, triglycerides, 
creatinine and urea. 
Statistical analysis 
Statistical analysis was carried out using GraphPad prism 
5.00.288 for Windows (GraphPad Software Inc., CA, USA).). 
For the antioxidant assay, experiment were carried out in 
triplicate. All data were expressed as Mean±Standard Error 
of the Mean (Mean±SEM). The analysis of variance (ANOVA) 
followed by Bonforroni post-test was performed for the 
comparison between two experimental groups. The 
differences were considered significant if p<0.05. 
RESULTS  
The antioxidizing activity of the LAMIC extract was assessed 
by DPPH, ABTS and FRAP assays.  
The amount of the LAMIC extract needed to decrease the 
initial radical DPPH concentration by 50% is used for the 
free radical scavenging activity and defined as IC50. To show 
values directly dependent on antioxidant activity, antiradical 
power (ARP) was calculated as 1/IC50. The free radical 
scavenging activity with the LAMIC extract and the Trolox 
used as positive control were of 45.38±3.21 µg/mL and 
7.17±0.31 µg/mL respectively (Table I). The ARP values 
were of 0.02 and 0.14 respectively for the LAMIC extract and 
the positive control Trolox. 
Using ABTS radical scavenging assay, for the determination 
of antiradical and antioxidant activities, the obtained results 
were also recorded in Table I and illustrated that the LAMIC 
extract have an antioxidant activity (66.45±18.76 µg/mL) 
even if lower than those of pure Trolox (3.98±0.03 µg/mL). 
The results of ABTS radical assays were also presented as 
Trolox Equivalent Antioxidant Capacity (TEAC) using Trolox 
as positive reference. The TEAC value of the LAMIC extract 
was 0.06 µg/mL confirming that it is also active even on 
ABTS cation and show good antioxidant capacity. 
The FRAP assay was used to investigate antioxidant activity 
of the LAMIC extract which, is based on the capacity of 
antioxidants to reduce ferric ions (Fe3+) to ferrous ions 
(Fe2+). Result was presented in Table I and show that the 
LAMIC extract has a powerful antioxidant property in the 
order of 211.34±15.92 mmol EAA/g using the Ascorbic acid 
used as standard (Table I). 
 
Table I: FRAP (mmol EAA/g), TEAC (Trolox Equivalent Antioxidant Capacity) and IC50 values (µg/mL) on the Free radical 
scavenging capacities of LAMIC activity measured with DPPH and ABTS assay. 
Substances DPPH ABTS FRAP 
 
IC50 (µg/mL) ARP IC50 (μg/mL) TEAC (μg/mL) (mmol EAA/g) 
LAMIC 45.38±3.21* 0.02 66.45±18.76* 0.06 211.34±15.92 
Trolox 7.17±0.31 0.14 3.98 ± 0.03 --- --- 
With ABTS : acide 2, 2’- azino bis-(3-ethylbenzothiazoline-6-sulfonique) ; ARP: anti radical power ; DPPH : 2,2-
Diphenylpicrylhydrazine ; TEAC : Trolox Equivalent Antioxidant Capacity ; FRAP: Ferric Reducing Antioxidant Power. Each 
value represent the mean±SEM of three independent experiments (n = 3 in triplicate; *p<0.001). 
Subchronic toxicity in rats 
Effect of LAMIC on rats body weight gain 
The figure 1 shows the body weight of rats before and 
during the LAMIC extract subchronic treatment. After 
observing body weight changes for 90 days, animals in both 
controls groups and the LAMIC extract treated groups at 
doses of 500, 1000 and 2000 mg/kg/bw showed increase in 
their body weights at a normal rate, indicating that the 
LAMIC extract had no significant effect on body weight 
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changes compared to the normal control groups. No death or 
hazardous signs of toxicity were recorded in the both sex of 
rats during period of experiment after oral treatment with 
LAMIC. Moreover, no abnormal change in the ingestive 
behavior and sensory nervous system responses were noted 
through the entire treatment. 
  
 
Figure 1: Mean body weight gain in female (A) and male (B) rats with the LAMIC extract treatment for 90 days. Data are 
presented as Mean±SEM (n = 10 males or n = 10 females for each group; p <0.05 is considered as statistically significant 
compared to the Control group). 
Effect of LAMIC on food consumption  
Results on food consumption are presented in Table II. 
During the recovery period, there was no significant change 
in food intake in all groups of both sex at all the doses of 
LAMIC tested as compared to the Control group. A slightly 
decrease in food consumption was observed in both treated 
male and female but without significant difference compared 
to the normal group. 
  
Table II: Mean food consumption by rat administrated LAMIC for 90 days (A: female group; B: male group). Data were 
expressed as Mean ± S.E.M.; p<0.05 versus Control group is considered as a significant difference. 
A: Female  LAMIC (mg/kg/bw) 
Weeks Control 500  1000 1500 
S1 19.00 15.14 17.84 16.16 
S2 18.91 16.34 16.31 16.70 
S3 17.76 15.99 15.77 16.21 
S4 17.87 15.37 15.93 15.83 
S5 16.03 14.35 14.10 14.81 
S6 16.61 18.70 14.90 15.76 
S7 16.16 16.20 15.16 16.33 
S8 14.44 13.54 15.04 14.13 
S9 15.46 14.05 17.19 15.84 
S10 17.00 15.30 16.17 15.76 
S11 16.36 14.70 15.41 15.33 
S12 17.01 15.13 16.24 14.68 
S13 12.36 11.09 12.19 11.35 
B :  Male  LAMIC (mg/kg/bw) 
   Weeks Control 500 1000 1500 
 S1 22.30 18.99 21.36 19.86 
 S2 23.71 18.38 19.93 20.44 
 S3 22.99 16.47 19.06 18.64 
 S4 24.71 17.71 17.73 18.11 
 S5 23.17 17.35 17.43 18.62 
 S6 22.36 19.27 18.90 18.29 
 S7 23.43 19.19 17.21 18.21 
 S8 18.59 16.73 16.27 17.25 
 S9 19.07 16.88 15.99 19.95 
 S10 19.96 19.45 18.63 19.77 
 S11 20.26 18.23 19.64 22.73 
 S12 21.07 20.06 19.94 20.49 
 S13 16.37 14.74 14.60 15.41 
Data were expressed as Mean ± S.E.M.; p<0.05 versus Control group is considered as a significant difference (n = 10 female or 
10 male). 
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Effect of LAMIC on rat water intake   
Animals food consumption was measured and recorded 
weekly for each group in all four groups during the 90-day 
study period and presented in Table III. Results shows that 
water consumption is very similar for all four groups even 
the little increase or decrease in values but no significant 
difference (p>0.05) is obtain compared to the Control group.
 
Table III: Water intake in Control and LAMIC-treated rats for 90 days. 
 
Doses (mg/kg/bw) 
Weeks Sex Control 500 1000 1500 
S1 
M 34.50±2.24 31.64±2.34 33.86±2.36 33.64±6.86 
F 33.50±2.42 29.43±4.94 33.93±5.65 27.21±3.45 
S2 
M 37.57±2.07 34.43±2.21 33.86±3.15 37.57±3.87 
F 34.50±2.45 30.14±3.61 33.64±3.46 29.79±3.31 
S3 
M 37.43±1.84 34.57±3.28 34.36±3.15 35.36±2.76 
F 33.71±1.41 30.64±3.01 32.71±1.65 29.52±1.80 
S4 
M 37.14±1.41 34.94±2.32 33.29±1.73 34.14±1.52 
F 36.14±1.44 27.79±1.87 32.79±1.68 29.92±2.39 
S5 
M 41.86±4.87 41.17±3.08 37.71±3.46 38.41±2.14 
F 34.86±3.29 33.10±3.30 32.79±4.30 32.22±3.08 
S6 
M 42.29±4.89 41.10±4.49 36.57±5.75 36.67±3.22 
F 34.36±4.26 31.35±1.78 33.64±2.54 29.52±2.39 
S7 
M 41.07±3.47 47.34±3.11 38.57±1.67 34.91±3.69 
F 34.36±2.73 31.70±1.24 33.29±2.61 31.19±2.04 
S8 
M 49.64±5.02 54.61±4.73 42.21 ±3.16 42.50±3.39 
F 35.57±2.46 32.68±4.25 36.50±3.37 31.75±2.67 
S9 
M 53.93±1.37 38.12±3.16 50.07±4.14 45.71±3.09 
F 35.50±3.37 32.41±4.98 41.86±4.96 33.02±3.09 
S10 
M 36.21±2.32 32.99±3.02 33.57±2.57 31.39±5.71 
F 31.43±2.56 29.29±2.46 31.43±2.44 29.92±3.18 
S11 
M 34.14±1.25 38.70±4.75 32.43±1.72 34.02±1.65 
F 29.93±2.01 26.25±2.58 29.44±3.88 25.32±2.68 
S12 
M 37.50±1.61 35.55±2.41 32.36±2.97 34.98±2.51 
F 33.36±2.48 28.39±3.18 33.25±4.77 28.17±3.07 
S13 
M 36.30±1.04 39.10±2.66 33.44±2.06 34.71±2.56 
F 31.00±2.26 26.50±4.21 31.11±3.22 27.67±3.23 
All data were expressed as Mean ± S.E.M.; p<0.05 versus Control group is considered as a significant difference (n = 10 female 
or 10 male). 
Effect of LAMIC on rat relative organ weights  
Table IV shows the relative organ weights of Control and 
LAMIC treated rats from subchronic toxicity study. The 
results that the heart, liver, lung, spleen, gonads (testes or 
ovaries) of the animals in experimental groups ranging from 
500, 1000 and 1500 mg/kg/bw had no significant difference 
(p>0.05) compared with their respective control groups. 
Moreother, in the macroscopic analysis of the different 
organs, there were not alterations in the relative weight or 
in the morphology that could be attributed to the LAMIC 
treatment.
 
Table IV: Relative organs weight from Control groups and LAMIC-treated groups after 90 days experiment and autopsy. 
All values are expressed as Mean±SEM and p<0.05 is considered as statistically significant compared to the Control group. (n = 
10; male or female for each group).  
 
                                                               LAMIC (mg/kg/bw) 
Organs Sex Control 500 1000 1500 
Heart 
M 0.29±0.02 0.31±0.07 0.31±0.03 0.29±0.03 
F 0.32±0.03 0.32±0.02 0.30±0.02 0.35±0.04 
Liver 
M 2.65±0.26 2.43±0.48 2.40±0.11 2.25±0.05 
F 2.66±0.24 2.50±0.18 2.34±0.31 2.47±0.18 
Lung 
M 0.51±0.06 0.51±0.08 0.53±0.05 0.52±0.08 
F 0.63±0.14 0.58±0.06 0.57±0.04 0.62±0.07 
Kidneys 
M 0.60±0.03 0.61±0.11 0.60±0.04 0.58±0.03 
F 0.66±0.07 0.62±0.03 0.60±0.06 0.61±0.05 
Spleen 
M 0.20±0.05 0.21±0.03 0.22±0.04 0.19±0.02 
F 0.23±0.04 0.23±0.02 0.28±0.15 0.24±0.04 
Gonads 
M 2.64±0.60 3.02±0.39 2.89±0.38 2.67±0.24 
F 0.09±0.04 0.22±0.31 0.08±0.03 0.09±0.04 
Belemnaba et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(5):1-8 
ISSN: 2250-1177                                                                                  [6]                                                                                 CODEN (USA): JDDTAO 
Effect of LAMIC on biochemical parameters  
The effect of LAMIC extract subchronic administration on 
biochemical parameters are presented in Table V. The 
LAMIC extract had no effect on serum electrolytes (Ca2+, 
PO42- and Cl-). In the kidney function parameters, results 
show that creatinine, total proteins, glucose, did not reveal 
any significant changes even urea is very slightly increase in 
LAMIC-treated animals. Furthermore, there was no 
significant difference in the level of tested liver function 
enzymes such as, such as ASAT and ALAT even there is a 
decrease in values of both treated sex compared to their 
respective untreated groups. However, the decrease in ASAT 
values were dose-dependent for both sex with exception in 
female at dose of 1000 mg/kg bw. The liver parameters such 
as total cholesterol had no significantly changed in LAMIC-
treated group; but triglycerides are slightly decrease in male 
and increase in female treated groups respectively but not 
significantly different to those of the Control group.
 
Table V: Serum clinical biochemistry parameters in males and female rats after 90-days LAMIC oral treatment. 
 
  LAMIC (mg/kg/bw) 
Parameters Sex Control 500 1000 1500 
Triglycerides (mg/dL) 
M 37.68±18.08 27.21±07.09 24.45±5.29 30.97±5.75 
F 30.60±10.75 27.94±06.95 33.99±6.34 34.66±32.11 
Total proteins (g/L) 
M 44.87±2.61 45.60±01.87 48.37±4.56 48.23±01.33 
F 47.28±2.56 48.84±01.70 49.08±2.87 46.59±02.45 
Calcium (mmol/L) 
M 03.04±0.11 03.01±0.05 03.03±0.05 03.05±0.04 
F 02.97±0.12 03.03±0.08 03.05±0.05 02.97±0.07 
Chloride (mmol) 
M 88.80±1.87 88.20±01.40 87.75±1.39 87.71±0.95 
F 88.40±1.07 87.63±0.74 88.63±1.06 89.00±01.50 
ASAT (UI/L) 
M 171.69±63.01 147.13±61.32 109.13±73.57 91.14±19.42 
F 178.84±66.62 164.21±52.16 176.52±70.80 103.30±17.19 
ALAT (UI/L) 
M 62.40±22.87 53.46±09.73 43.76±6.82 49.34±11.68 
F 39.20±09.12 35.70±04.86 38.28±10.77 31.53±06.63 
Phosphorus (mmol/L) 
M 03.54±01.40 03.07±0.45 02.71±0.47 02.69±0.21 
F 02.51±0.42 02.48±0.24 02.90±0.67 02.41±0.20 
Glucose (mg/dL) 
M 87.64±27.20 101.29±18.93 101.80±15.69 115.30±26.39 
F 85.35±16.98 78.36±09.26 79.43±19.84 88.00±12.11 
Total Cholesterol (mg/dL) 
M 53.96±11.23 53.30±08.22 48.73±11.51 44.95±15.17 
F 48.45±11.59 49.09±13.01 48.49±7.41 43.70±18.74 
Creatinine (µmol/L) 
M 64.38±12.20 60.10±06.20 57.91±4.41 65.53±05.45 
F 63.18±06.27 62.54±07.23 54.41±5.17 59.95±02.83 
Urea (mg/dL) 
M 50.86±05.34 53.76±09.08 44.79±8.07 54.19±08.99 
F 48.15±08.16 50.48±07.60 53.14±15.01 53.51±09.67 
With ASAT = aspartate aminotransferase and ALAT = alanine aminotransferase. All data are expressed as Mean±SEM; p<0.05 is 
considered as statistically significant compared to the Control group (n = 10; male or female for each group). 
 
DISCUSSION 
Lannea microcarpa is a plant widely used in Burkina Faso 
traditional medicine to treat several diseases including 
hypertension. Previous preclinical studies showed that 
extracts from this species have vasodilatory effects, 
antihypertensive properties and are powerful inhibitors of 
purified phosphodiesterases 5, 15. Others studies also indicate 
the presence of chemical groups compounds such as 
steroids, triterpenoids, coumarins, saponins, anthocyanins, 
tannins etc. in the extracts of Lannea microcarpa trunk barks 
5, 8, 15. Moreover, previous studies have shown that the acute 
toxicity of the aqueous extract from Lannea microcarpa 
trunk bark was of LD50 = 5000 mg/kg bw, while the 28 days 
subacute oral toxicity study indicate no mortality observed 
for doses of 100, 500, and 1000 mg/kg bw in both sex 6. In 
addition, a prototype formulation and the quality control of 
the plant material were also investigate. This prototype 
formulation named LAMIC is a phytomedicine prototype 
based on freeze-dried aqueous extract of the trunk bark of 
Lannea microcarpa 2. However, any study to date has been 
undertake to verify that this phytomedicine prototype after 
formulation has retained its potential biological effects and 
might be safe for its possible use in humans. It is the reason 
why, the present study aims to explore in the first time, the 
antioxidant activity and the subchronic toxicity of LAMIC 
prototype formulation in order to provide scientific evidence 
in favor to the therapeutic properties and the future safety 
use in the care of hypertension.  
Indeed, it is well know that free radical play a crucial role in 
the pathogenesis of several disease including pulmonary, 
cancer, rheumatoid, diabetes, cardiovascular diseases, 
atherosclerosis, hypertension, ischemia/reperfusion injury, 
etc 16-20. Thus, the present study evaluate the LAMIC 
antioxidant activity by using three methods that are DPPH 
radical scavenging activity assay, ABTS radical cation 
scavenging activity assay and the FRAP assay. Results 
showed that the LAMIC extract has a good DPPH scavenging 
activity, even six time lower to that of Trolox with IC50 of 
45.38±3.21 µg/mL and 7.17±0.31 µg/mL respectively. In 
contrast, the antioxidant activity obtained by the ABTS assay 
of this extract was very lower than that of the Trolox 
(66.45±18.76 µg/mL and 3.98 ± 0.03 µg/mL respectively). 
This difference may be explain by the type of antioxidant 
method assay used. Indeed, several studies indicated that 
the same substance might give different results for their 
antioxidant activity depending on the method used 21, 22. 
Because the ABTS method evaluates the antioxidant activity 
of hydrophilic and lipophilic compounds in a substance , the 
low antioxidant potency of LAMIC phytomedicine may be 
due to the presence of excipients in the formulation that 
would inhibit phenolic compounds 23. Indeed, a study 
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already showed that an aqueous extract from Lannea 
microcarpa at the base of the LAMIC formulation has an anti-
radical activity superior to that of Trolox using ABTS assay 
24. Above all, the FRAP method confirmed the reducing 
power of LAMIC (211.34 ± 15.92 mmol EAA/g) using 
Ascorbic acid as standard. This reducing power could be 
attributed to the presence of polyphenolic compounds in 
LAMIC extract, which are known to have antioxidant activity 
by their ability to capture free radicals and metal 
complexation 25-27. The present results are in line with a 
previous study, which showed that the fruits of Lannea 
microcarpa have a good antioxidant activity that was 
correlated with the content in polyphenolic compounds and 
flavonoids 4. 
The results of the subchronic 90-day oral toxicity study of 
the LAMIC extract demonstrated that daily oral 
administration of LAMIC at doses of 500, 1000 and 1500 
mg/kg/day has no negative influence on the behavior or 
adverse clinical signs and mortality in all experiment groups. 
It is well know that body weight changes or and altered 
clinical observations weight serve as a sensitive index for the 
general status of animals 28, 29. The present results suggested 
that the LAMIC did not affect food and water intake through 
animals appetite suppression since comparison of food 
consumption, water intake and rats body weight gain 
revealed no statistically different between LAMIC-treated rat 
and controls.  However, a very slight decrease in food 
consumption was observed in treated groups especially in 
the last week of treatment, although no anorexia was 
recorded.  
Otherwise, the relative organ weights of LAMIC-treated 
animals after autopsy showed no significant difference from 
those of the Control group, suggesting that there was no 
impact on the relative organ weights of the treated rats at 
any doses of LAMIC investigated.  
The alteration in serum biochemical parameters has a higher 
predictive value for drug toxicity in humans, and is one of 
the most commonly used diagnostic index in clinical practice 
30. In the present subchronic toxicity study, there was no 
significant change in all the biological parameters of blood 
serum analyzed in the treated compared to the Control 
groups. Alanine amino transaminase (ALAT) and aspartate 
amino transaminase (AST) are widely used as biomarkers 
for the evaluation of liver damage due to drugs or any other 
hepatotoxin 31. Their increases are signs of hepatocellular 
degeneration and necrosis 32, 33. Nevertheless, ALAT and 
ASAT levels may also rise rapidly in the liver because of 
several others reasons including hepatitis, cirrhosis, and 
hepatotoxicity of some drugs 34. In the present study, the 
concentration of these two enzymes (ALAT and ASAT) from 
the LAMIC-treated groups were not significantly different 
compared to the Control group suggesting no damage in the 
animals liver. Likewise, decrease in cholesterol and 
triglyceride levels are proven effective in reducing the 
incidence of cardiovascular disease 35-38. In this study, a 
slight but not significant decrease in total cholesterol and 
triglyceride compared to the Control group was observed at 
the dose of 1500 mg/kg bw suggesting that LAMIC might 
possessed a protective effect on the cardiovascular system. 
This result support a recent study in where ethyl acetate 
fraction from Lannea microcarpa is able to correct 
angiotensin II-induced hypertension and endothelium 
dysfunction in an in vivo model 15. In addition, creatinine is a 
serum metabolite that the level could but not necessary 
indicate the physiology of the kidney 39, 40. In this study, no 
significant change in creatinine values were noticed in 
LAMIC-treated and Control groups suggesting that this 
specific organ is not damage. Forevermore, results notice a 
very slightly increase of urea level in LAMIC-treated animals 
but not significantly different to those of the Control group 
confirming that there is no renal impairment. This result 
could be in line with a previous study in where an aqueous 
extract from Lannea microcarpa has just a moderate diuretic 
activity in normotensive rats 41. Moreover, the LAMIC extract 
has no effect on serum electrolytes (Ca2+, PO42- and Cl-) just 
like total proteins and glucose level since most of these 
differences were very small, not dose-dependent, and/or not 
found in both sexes. Thus, none of these differences were 
considered to be toxicological or biological significance.  
Above all, the macroscopic examination of vital organs such 
as the heart, liver, lung, spleen and gonads revealed no 
treatment-related changes due to administration of the 
LAMIC prototype phytomedicine. So, the subchronic toxicity 
that has not revealed harmful effects that affect the target 
organs of the animals already leads to the conclusion that 
there is a possibility of safe use of LAMIC. 
In summary, the LAMIC has an antioxidant profile without 
any obvious toxicity in treated groups. It is the first time that 
the antioxidant properties of the LAMIC prototype 
phytomedicine from Lannea microcarpa were assessed. 
Moreover, the present study is the first and the longest 
duration toxicity study of this prototype to date. There were 
no biologically or toxicologically significant findings showed 
in both sexes rats at the doses of 500, 1000 and 1500 mg/kg 
bw. Thus, the LAMIC recorded potent antioxidant activity 
and the lack of toxicity in the present investigation further 
support the oral safety used of the LAMIC phytomedicine. 
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